TOI
Oncology InstituteDNasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-21
Current thesis
Material positive clinical data or realization of collaboration milestones without dilution would likely re-rate TOI sharply versus current levels; limited float and event leverage could amplify gains.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -5.1.
What can break
Inability to collect partner milestones, coupled with a dilutive equity raise while clinical progress is slow, would likely drive the stock toward low-penny territory or trigger trading suspension scenarios.
Momentum
89
Value
37
Sentiment
26
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.36 · Bull $1.20 · Bear $0.12
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-17 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $8.40
Why
Momentum89 · Δ7d -5.1
Value37 · Δ7d 0.0
Sentiment26 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
89
26% active weight
Current posture
7d trendSoftening
Δ7d
-5.1
Δ21d
-3.9
Value
37
39% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.2
Sentiment
26
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade D. Momentum 89.4 / Value 36.5 / Sentiment 26.0
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$528.91M
Beta
0.17
Shares Out
99.98M
P/E (TTM) · Derived
-9.7
P/S (TTM)
0.84
P/FCF (TTM) · Derived
-19.68
Rev YoY
+41.2%
EPS YoY
-90.1%
Gross Margin
+13.9%
Op Margin
-8.9%
Net Debt
$70.19M
Current Ratio
1.47
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology